Literature DB >> 19830430

[Pseudo-mesotheliomatous adenocarcinoma of the lung].

K Aumann1, J Günter, N Freudenberg.   

Abstract

Both pathologists and clinicians are challenged by the diagnosis of a particular variant of the peripheral adenocarcinoma with involvement of the pleura parietalis, the so-called pseudo-mesotheliomatous adenocarcinoma of the lung (PMAC), which is hard to differentiate from epithelioid mesothelioma on imaging and cytology, macroscopically as well as histologically. However, the exact diagnosis is not only crucial for the patient's therapy but also for insurance matters. Immunohistochemical evaluation represents a quick and a relatively cheap tool for which a few antibody panels have been proposed in recent years as being suitable to distinguish between these two entities. One of the positive markers for epithelioid mesothelioma most often suggested seems to be calretinin. We would like to report on a case of PMAC with the special feature of positive calretinin immunohistochemical staining. Using histochemistry and a few additional antibodies we were able to reliably characterize the tumor and provide the patient with appropriate therapy. This article gives a short overview of the possibilities available for distinguishing between these two entities in the context of a case report.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19830430     DOI: 10.1007/s00292-009-1235-z

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  31 in total

1.  Pseudomesotheliomatous carcinoma involving pleura and peritoneum: A clinicopathologic and immunohistochemical study of three cases.

Authors:  I A Shah; J R Salvatore; T Kummet; O S Gani; L A Wheeler
Journal:  Ann Diagn Pathol       Date:  1999-06       Impact factor: 2.090

Review 2.  After Helsinki: a multidisciplinary review of the relationship between asbestos exposure and lung cancer, with emphasis on studies published during 1997-2004.

Authors:  Douglas W Henderson; Klaus Rödelsperger; Hans-Joachim Woitowitz; James Leigh
Journal:  Pathology       Date:  2004-12       Impact factor: 5.306

3.  Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.

Authors:  Kei Kushitani; Yukio Takeshima; Vishwa Jeet Amatya; Osamu Furonaka; Akio Sakatani; Kouki Inai
Journal:  Pathol Int       Date:  2007-04       Impact factor: 2.534

4.  The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.

Authors:  Nelson G Ordóñez
Journal:  Am J Surg Pathol       Date:  2003-08       Impact factor: 6.394

Review 5.  [Pleuromesothelioma -- psychology and pathogenesis].

Authors:  K-M Müller
Journal:  Pneumologie       Date:  2004-09

6.  Thyroid transcription factor-1 and cytokeratins 7 and 20 in pulmonary and breast carcinoma.

Authors:  H A Harlamert; J Mira; P A Bejarano; R P Baughman; M A Miller; J A Whitsett; R Yassin
Journal:  Acta Cytol       Date:  1998 Nov-Dec       Impact factor: 2.319

7.  Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity.

Authors:  Hadi Yaziji; Hector Battifora; Todd S Barry; Harry C Hwang; Carlos E Bacchi; Martin W McIntosh; Steven J Kussick; Allen M Gown
Journal:  Mod Pathol       Date:  2006-04       Impact factor: 7.842

8.  The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.

Authors:  N G Ordóñez
Journal:  Am J Surg Pathol       Date:  1989-04       Impact factor: 6.394

9.  Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.

Authors:  A S Abutaily; B J Addis; W R Roche
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

10.  [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].

Authors:  Ewa Szczepulska-Wójcik; Renata Langfort; Kazimierz Roszkowski-Sliz
Journal:  Pneumonol Alergol Pol       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.